Ozmosi | Donzakimig Drug Profile
Contact Us
Drug Profile
Using advanced filters...
Advanced Search [+]

Donzakimig

Pronounced as: don-ZAK-i-mig

Alternative Names: Donzakimig, ucb-1381, ucb 1381, ucb1381
Clinical Status: Active
Latest Update: 2025-10-20
Latest Update Note: Clinical Trial Update

Product Description

UCB is developing ucb-1381, a biologic for treatment of Atopic Dermatitis.

Mechanisms of Action: IL22 Inhibitor, IL13 Inhibitor

Novel Mechanism: Yes

Modality: Bispecific Antibody

Route of Administration: Intravenous, Subcutaneous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: UCB
Company Location:
Company Founding Year: 1928
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Donzakimig

Countries in Clinic: United States

Active Clinical Trial Count: 2

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Dermatitis, Atopic

Phase 1: Healthy Volunteers

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT05277571

 UP0110

P2

Completed

Dermatitis, Atopic

2025-07-17

2%

2025-10-23

NCT06716879

 UP0142

P1

Completed

Healthy Volunteers

2025-04-04

88%

2025-04-16

Primary Endpoints

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions